

27 - References

References

Schizophrenia and related psychoses CHAPTER 1 ■ ■ Combined antipsychotic medications are commonly prescribed and this practice seems to be relatively resistant to change. ■ ■ As a minimum requirement, all patients who are prescribed combined antipsychotic medications should be systematically monitored for adverse effects (including an ECG) and any beneficial effect on the symptoms of psychotic illness carefully documented. ■ ■ Some antipsychotic polypharmacy strategies (e.g. combinations with aripiprazole) show clear benefits for tolerability but not efficacy.

References

1. Harrington M, et al. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. *Psychiatr Bull* 2002; 26:414-418.
2. Gallego JA, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. *Schizophr Res* 2012; 138:18-28.
3. Sneider B, et al. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: a nation-wide pharmacoepidemiological study. *Eur Neuropsychopharmacol* 2015; 25:1669-1676.
4. Procyshyn RM, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. *J Clin Psychiatry* 2010; 71:566-573.
5. Aggarwal NK, et al. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. *J Clin Psychopharmacol* 2012; 32:323-328.
6. Barnes T, et al. Antipsychotic long acting injections: prescribing practice in the UK. *Br J Psychiatry Suppl* 2009; 52:S37-S42.
7. Novick D, et al. Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study. *J Nerv Ment Dis* 2012; 200:637-643.
8. Paton C, et al. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. *Br J Psychiatry* 2008; 192:435-439.
9. Royal College of Psychiatrists. Prescribing Observatory for Mental Health. Topic 1h & 3e: Prescribing of antipsychotic medication in adult mental health services, including high dose, combined, and PRN. CCQI 442. 2022 (last accessed February 2025); <https://www.rcpsych.ac.uk/improving-care/ccqi/national-clinical-audits/pomh>.
10. Correll CU, et al. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. *Psychiatr Clin North Am* 2012; 35:661-681.

11. Baandrup L, et al. Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis. *Eur J Health Econ* 2012; 13:355–363.
12. Kadra G, et al. Predictors of long-term (≥ 6 months) antipsychotic polypharmacy prescribing in secondary mental healthcare. *Schizophr Res* 2016; 174:106–112.
13. Grech P, et al. Long-term antipsychotic polypharmacy: how does it start, why does it continue? *Ther Adv Psychopharmacol* 2012; 2:5–11.
14. Malandain L, et al. Correlates and predictors of antipsychotic drug polypharmacy in real-life settings: results from a nationwide cohort study. *Schizophr Res* 2018; 192:213–218.
15. Fleischhacker WW, et al. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. *Int J Neuropsychopharmacol* 2014; 17:1083–1093.
16. Korkmaz Ş A, et al. Real-world evidence of antipsychotic monotherapy versus polypharmacy in the treatment of schizophrenia spectrum disorders. *J Clin Psychopharmacol* 2024; 44:250–257.
17. Ortiz-Orendain J, et al. Antipsychotic combinations for schizophrenia. *Schizophr Bull* 2018; 44:15–17.
18. Galling B, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. *World Psychiatry* 2017; 16:77–89.
19. Essock SM, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. *Am J Psychiatry* 2011; 168:702–708.
20. Hori H, et al. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. *J Psychiatr Res* 2013; 47:1843–1848.
21. Shakir M, et al. The effect on relapse rate and psychiatric symptomatology: switching a combination of first- and second-generation anti psychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders: a pragmatic randomized open-label trial (SwAP trial). *Schizophr Res* 2022; 243:187–194.
22. Constantine RJ, et al. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial. *Schizophr Res* 2015; 166:194–200.
23. Katona L, et al. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. *Schizophr Res* 2014; 152:246–254.
24. Tiihonen J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. *JAMA Psychiatry* 2019; 76:499–507.
25. Goff DC. Can adjunctive pharmacotherapy reduce hospitalization in schizophrenia? Insights from administrative databases. *JAMA Psychiatry* 2019; 76:468–470.
- 26 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 26. Tiihonen J, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. *JAMA Psychiatry* 2017; 74:686–693.
27. López de Torre A, et al. Antipsychotic polypharmacy: a needle in a haystack? *Gen Hosp Psychiatry* 2012; 34:423–432.
28. Carnahan RM, et al. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. *Acta Psychiatr Scand* 2006; 113:135–141.
29. Gombert RF. Interaction between olanzapine and haloperidol. *J Clin Psychopharmacol* 1999; 19:272–273.
30. Suzuki T, et al. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia:

an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. *Hum Psychopharmacol* 2008; 23:455–463.

31. Gallego JA, et al. Safety and tolerability of antipsychotic polypharmacy. *Expert Opin Drug Saf* 2012; 11:527–542. 32. Hashimoto Y, et al. Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients. *Psychiatry Clin Neurosci* 2012; 66:405–410. 33. Sorensen HJ, et al. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis. *Eur Neuropsychopharmacol* 2013; 23:872–878. 34. Dome P, et al. Paralytic ileus associated with combined atypical antipsychotic therapy. *Prog Neuropsychopharmacol Biol Psychiatry* 2007; 31:557–560. 35. Hedges DW, et al. New-onset seizure associated with quetiapine and olanzapine. *Ann Pharmacother* 2002; 36:437–439. 36. Beelen AP, et al. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. *Hum Exp Toxicol* 2001; 20:215–219. 37. Eyles E, et al. Antipsychotic medication and risk of metabolic disorders in people with schizophrenia: a longitudinal study using the UK clinical practice research datalink. *Schizophr Bull* 2024; 50:447–459. 38. Baandrup L, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. *J Clin Psychiatry* 2010; 71:103–108. 39. Chen Y, et al. Antipsychotics and risk of natural death in patients with schizophrenia. *Neuropsychiatr Dis Treat* 2019; 15:1863–1871. 40. Tiihonen J, et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. *Arch Gen Psychiatry* 2012; 69:476–483. 41. Waddington JL, et al. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. *Br J Psychiatry* 1998; 173:325–329. 42. Kadra G, et al. Long-term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality. *Acta Psychiatr Scand* 2018; 138:123–132. 43. Joukamaa M, et al. Schizophrenia, neuroleptic medication and mortality. *Br J Psychiatry* 2006; 188:122–127. 44. Centorrino F, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. *Am J Psychiatry* 2004; 161:700–706. 45. Taylor D, et al. Co-prescribing of atypical and typical antipsychotics: prescribing sequence and documented outcome. *Psychiatr Bull* 2002; 26:170–172. 46. Kreyenbuhl J, et al. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. *Psychiatr Serv* 2007; 58:983–990. 47. Nielsen J, et al. Psychiatrists' attitude towards and knowledge of clozapine treatment. *J Psychopharmacol* 2010; 24:965–971. 48. Ascher-Svanum H, et al. Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia. *Neuropsychiatr Dis Treat* 2012; 8:113–118. 49. Goren JL, et al. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. *Psychiatr Serv* 2013; 64:527–533. 50. Howes OD, et al. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. *Br J Psychiatry* 2012; 201:481–485. 51. Thompson JV, et al. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. *J Psychopharmacol* 2016; 30:436–443. 52. Shiloh R, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. *Br J Psychiatry* 1997; 171:569–573. 53. Josiassen RC, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. *Am J Psychiatry* 2005; 162:130–136. 54. Paton C, et al. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. *J Clin Psychopharmacol* 2007; 27:198–204. 55. Barbui C, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? *Schizophr Bull* 2009; 35:458–468. 56.

Taylor DM, et al. Augmentation of clozapine with a second antipsychotic: a meta-analysis of randomized, placebo-controlled studies. *Acta Psychiatr Scand* 2009; 119:419–425. 57. Fleischhacker WW, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. *Int J Neuropsychopharmacol* 2010; 13:1115–1125. 58. Cooper SJ, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. *J Psychopharmacol* 2016; 30:717–748. 59. Byerly MJ, et al. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. *Schizophr Res* 2009; 107:218–222. 60. Liu X, et al. Co-prescription of aripiprazole on prolactin levels in long-term hospitalized chronic schizophrenic patients with co-morbid type 2 diabetes: a retrospective clinical study. *Front Psychiatry* 2023; 14:1124691.

Schizophrenia and related psychoses CHAPTER 1 61. Jiang Q, et al. Treatment of antipsychotic--induced hyperprolactinemia: an umbrella review of systematic reviews and meta-analyses. *Front Psychiatry* 2024; 15:1337274. 62. Shim JC, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo- controlled trial. *Am J Psychiatry* 2007; 164:1404–1410. 63. Trives MZ, et al. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. *J Clin Psychopharmacol* 2013; 33:538–541. 64. Chen CK, et al. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. *Prog Neuropsychopharmacol Biol Psychiatry* 2010; 34:1495–1499. 65. Lin SK. Antipsychotic polypharmacy: a dirty little secret or a fashion? *Int J Neuropsychopharmacol* 2020; 23:125–131. 66. Guinart D, et al. Antipsychotic polypharmacy in schizophrenia: why not? *J Clin Psychiatry* 2020; 81:19ac13118.

Revision #1

Created 2026-01-04 20:13:35 UTC by Omar Ayman

Updated 2026-01-04 20:13:35 UTC by Omar Ayman